BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/11/2025 8:20:58 AM | Browse: 94 | Download: 254
 |
Received |
|
2025-08-04 11:21 |
|
Peer-Review Started |
|
2025-08-04 11:21 |
|
First Decision by Editorial Office Director |
|
2025-08-15 08:53 |
|
Return for Revision |
|
2025-08-15 08:53 |
|
Revised |
|
2025-08-27 07:01 |
|
Publication Fee Transferred |
|
2025-08-28 06:00 |
|
Second Decision by Editor |
|
2025-11-03 02:43 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-11-03 09:55 |
|
Articles in Press |
|
2025-11-03 09:55 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-11-28 03:30 |
|
Publish the Manuscript Online |
|
2025-12-11 08:20 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Preliminary exploration of programmed death 1 inhibitor combined with fruquintinib and docetaxel for advanced colorectal cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Xian-Yang Meng, Yu-Mei Cai, Ning-Ning Sun, Wen-Hua Zhang, Rui-Xue Cui, Long Zhang, Cheng-Cheng Zheng, Zhen Sun, Wei-Xuan Luo and Feng-Wei Wang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Feng-Wei Wang, MD, PhD, Department of Oncology, Tianjin Union Medical Center of Nankai University, No. 190 Jieyuan Road, Tianjin 300121, China. wfengwei2004@163.com |
| Key Words |
Immune checkpoint inhibitor; Fruquintinib; Docetaxel; Advanced microsatellite stable/proficient mismatch repair colorectal cancer; Programmed death 1 |
| Core Tip |
This study aimed to evaluate the efficacy and safety of a novel triple-combination regimen - programmed death 1 inhibitor + fruquintinib + docetaxel - as a third-line treatment for advanced microsatellite stable/proficient mismatch repair colorectal cancer. Primary endpoints included progression-free survival and disease control rate. Intention-to-treat analysis showed median progression-free survival 7.0 months, median overall survival 18.5 months, disease control rate 61.5%, with manageable toxicity. This study preliminarily validates the synergistic effect of programmed death 1 inhibitors combined with fruquintinib and docetaxel in microsatellite stable colorectal cancer, providing a novel strategy with translational significance for later-line treatment in advanced patients. |
| Publish Date |
2025-12-11 08:20 |
| Citation |
Meng XY, Cai YM, Sun NN, Zhang WH, Cui RX, Zhang L, Zheng CC, Sun Z, Luo WX, Wang FW. Preliminary exploration of programmed death 1 inhibitor combined with fruquintinib and docetaxel for advanced colorectal cancer. World J Gastrointest Oncol 2025; 17(12): 112548 |
| URL |
https://www.wjgnet.com/1948-5204/full/v17/i12/112548.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v17.i12.112548 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
